Product Details
| Product Name:
Cl-amidine hydrochloride |
CAS No.:
1373232-26-8 |
| Purity:
98.14% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | Cl-amidine hydrochloride |
| Description | Cl-amidine hydrochloride is an orally available PAD inhibitor that blocks histone 3 deimination and neutrophil extracellular trap formation and improves survival in septic mice. It induces apoptosis in cancer cells and induces miR-16 to cause cell cycle arrest. |
| In vitro | METHODS: Mouse primary splenocytes were treated with 1 μg/mL LPS and 10 μM Cl-amidine. Cell culture supernatants were collected 6 hours after treatment. TNF-α and pro-inflammatory properties of plasma and cell culture supernatants were determined by ELISA. Cytokine expression.
RESULTS Cl-amidine decreased the concentration of TNF-α in plasma. At the same time, Cl-amidine treatment could significantly reduce the concentrations of these pro-inflammatory cytokines (IL-1β, IL-6). [1]
METHODS: HT29 and TK6 cells were treated with Cl-amidine (0, 5, 10, 15, 25, 50 μg/mL, 24 hours) to detect whether Cl-amidine could induce apoptosis of HT29 and TK6 cells.
RESULTS Cl-amidine induced apoptosis of these cells in a dose-dependent manner. [2] |
| In vivo | METHODS: Cl-amidine (40 mg/kg) was administered intraperitoneally to mice 1 hour after cecal ligation and puncture (CLP) to observe the effect of Cl-amidine on protecting mice from sepsis-induced lethality. RESULTS Cl-amidine protected mice from sepsis-induced lethality, and Cl-amidine-treated CLP animals had a higher long-term survival rate. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 19.23 mg/mL (55.38 mM), Sonication is recommended.
H2O : 50 mg/mL (143.99 mM), Sonication is recommended.
|
| Keywords | Cl amidine hydrochloride | miRNA-16 | Protein Arginine Deiminase | Cl-amidine | inhibit | MicroRNA | Peptidylarginine Deiminase | Cl-amidine Hydrochloride | Clamidine hydrochloride | Inhibitor | miRNA | microRNA-16 | colitis | sepsis | Apoptosis | miR-16 |
| Inhibitors Related | Stavudine | 5-Fluorouracil | Acetylcysteine | Kaempferol | Myricetin | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Metronidazole | Sorafenib | Tributyrin | Lidocaine hydrochloride |
| Related Compound Libraries | Apoptosis Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | Inhibitor Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:1043444-18-3
$0.00 / 100mg
-
CAS:913723-61-2
$1980.00 / 50mg
-
CAS:1404060-15-6
$1520.00 / 25mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$0.00/1KG |
VIP1Y
|
Shandong Huizhihan Supply Chain Co., Ltd
|
2024-12-11 |
|
|
$117.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
|
|
$37.00/1mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
